Abbott Laboratories Corporation

Abbvie Inc.

Dennis Y Lee

Akwete L Adjei

Pramod K Gupta

Anthony J Hlinak

Yi Gao

Kennan C Marsh

Rong Ron Liu

Kevin R Engh

Ji Zhou

Mou-Ying Fu Lu

Sean E Mackey

Martin J Gibler

Qinghai Pan

Tzuchi R Ju

Vivian Wu

Gowdahallin N Subba Rao

Jack Zheng

Tong Zhu

Claudia M Davila

David Leblond

Shyamala C Jayaraman

A syringe includes a barrel, a plunger, and a sealing member creating a seal between the plunger and the barrel. The barrel includes a first portion with a first inner diameter and a second portion with a second inner diameter that is larger than the first inner diameter. The sealing member engages the first portion of the barrel to give rise to a first contact pressure when the barrel is filled with product. The first contact pressure is sufficient to maintain a gas-tight seal over the expected temperature ranges &#x2212;25&#xb0; C. to 40&#xb0; C. A first force is applied to the plunger to overcome the first contact pressure and move the plunger out of the first portion and into the second portion to dispense product. The sealing member engages the second portion of the barrel to give rise to a second contact pressure that is lower than the first contact pressure. A second force lower than the first force is sufficient to overcome the second contact pressure and move the plunger in the second portion to continue dispensing product. The syringe may include a restraining element for accommodating expansion of the product during freezing.

Syringe with two-stage sealing pressure

The present invention is directed to a process for preparing a formulation comprising a lipid-regulating agent dissolved in a supercritical fluid, spraying the solution through a nozzle to form small particles of the lipid-regulating agent, forming a suspension of the particles of said lipid-regulating agent in a liquid, and collecting the particles.

Formulations comprising lipid-regulating agents

The present invention relates to methods and formulations for administering a dopamine agonist to the airways of a patient. The preferred dopamine agonist is selected from (5aR-trans)-4,5,6,7,11b-hexahydro-2-propylbenzo&lsqb;f&rsqb;thieno&lsqb;2,3-c&rsqb;quinoline- 9,10) -diol, diacetate (ester) hydrochloride. The delivery method relates to certain aerosol formulations and liquid formulations which are administered into the airways to provide effective delivery of the dopamine agonists to the receptor.

Formulations for pulmonary delivery of dopamine agonists

The present invention provides a process for the continuous milling of aerosol pharmaceutical formulations which contain solids by milling in the aerosol propellant.

Process for the continuous milling of aerosol pharmaceutical

The present invention provides a process and apparatus for the continuous milling of aerosol pharmaceutical formulations which contain solids by milling in the aerosol propellant.

Apparatus for the continuous milling of aerosol pharmaceutical

Pharmaceutical compositions for aerosol delivery comprising (a) a medicament, (b) a non-chlorofluorocarbon propellant, and (c) a vegetable oil or a pharmaceutically acceptable derivative thereof, as well as a method for preparing such compositions in which unwanted aggregation of the medicament is prevented without the use of surfactants, protective colloids or cosolvents.

Aerosol drug formulations containing vegetable oils

Compositions useful for the percutaneous administration of leuprolide comprise from about 1 to about 100 mg/ml of leuprolide in its free base form, a cutaneous membrane penetration enhancing component, and a pharmaceutically acceptable carrier. The cutaneous membrane transport enhancing component comprises from about 1 percent to about 15 percent urea, from 1 percent to about 5 percent menthol, from about 0.5 percent to about 5 percent methyl salicylate, and from about 0.5 percent to about 5 percent camphor, all percentages expressed in weight/volume based upon the total volume of the composition.

Formulations and method of the percutaneous administration of leuprolide

Growing community of inventors

Highland Park, IL, United States of America

Dennis Y Lee